A research team led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) unveiled an improved CRISPR-Cas9 strategy aimed at increasing precision and safety in human hematopoietic stem cells. The work targets a core translation barrier for genome editing therapies: minimizing unwanted editing outcomes while keeping editing efficient enough for clinical use. By focusing on HSCs—cells that can seed durable immune and blood system recovery—the platform is designed to reduce risk associated with genome editing variability and off-target activity. The study’s framing positions the advance as a step toward enabling broader clinical application of gene editing in blood disorders. If the improved precision translates in vivo, it could inform dosing, manufacturing, and regulatory expectations for next-generation edited cell therapies entering clinical development.